GlassScriptPhysician profile
John H Ellis
NPI 1316088669
$10,743.10
in general payments reported to CMS, 2019-2025
37 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $1,252 · 2021: $1,487 · 2022: $1,025 · 2023: $1,501 · 2024: $1,747 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,104.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,683.84 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,487.28 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,475.69 | 2019-2024 | Xarelto |
| Amgen INC. | $1,281.46 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $644.85 | 2019-2025 | Watchman Flx, Synergy, Bodyguardian |
| Pfizer INC. | $570.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $439.23 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.70 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $362.74 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $325.88 | 2019-2024 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $314.36 | 2021-2025 | Verquvo |
| Abbott Laboratories | $267.90 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Daiichi Sankyo INC. | $189.50 | 2019-2025 | Injectafer |
| Medtronic, INC. | $154.12 | 2023-2024 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Esperion Therapeutics, INC. | $147.06 | 2021-2025 | Nexletol |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $137.35 | 2024-2025 | |
| Vifor Pharma, INC. | $101.75 | 2019-2021 | |
| Amarin Pharma, INC. | $87.62 | 2019-2022 | |
| Heartflow, INC. | $84.00 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $65.72 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $64.28 | 2025 | Nimbl, Flexitouch Plus |
| Alnylam Pharmaceuticals INC. | $53.96 | 2024-2025 | Onpattro |
| Philips North America LLC | $52.45 | 2024-2025 | (Ck7) Extended Holter, Coronary Other |
| Impulse Dynamics (USA) INC. | $49.69 | 2024 | Optimizer |
| Shockwave Medical, INC | $40.87 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.55 | 2019-2023 | |
| Davol INC. | $29.66 | 2020 | |
| Glaxosmithkline, LLC. | $27.55 | 2025 | Arexvy, Shingrix |
| Bridgebio Pharma, INC. | $22.73 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $20.65 | 2024 | Opsumit |
| Acarix USA INC. | $16.78 | 2023 | Cadscor System |
| Biotronik INC. | $16.57 | 2022 | |
| Infobionic, INC | $16.18 | 2023 | Mome Kardia |
| Regeneron Healthcare Solutions, INC. | $15.63 | 2019 | |
| Altathera Pharmaceuticals LLC | $14.71 | 2024 | Sotalol Hydrochloride |
| Kowa Pharmaceuticals America, INC. | $12.46 | 2020 | |
| Terumo Medical Corporation | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.